SCHEMBL7948710

SCHEMBL7948710

CCCNn1c(CBr)c(C(=O)N[C@H](c2cccc(F)c2)C2CCC2)c2cccc(F)c2c1=O

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.42
TACR3 P29371 10/20 0.41
OPRL1 P41146 1/20 0.33
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPK1 P28482 1/20 0.32
KMT2A Q03164 1/20 0.32
HTR3E A5X5Y0 1/20 0.32
HTR3B O95264 1/20 0.32
HTR3A P46098 1/20 0.32
HTR3D Q70Z44 1/20 0.32
HTR3C Q8WXA8 1/20 0.32
PDE2A O00408 1/20 0.32
SLC6A2 P23975 1/20 0.31
REN P00797 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11917790 0.93 CYP2C9 (0.43) CYP2C9TACR3OPRL1MEN1ALDH1A1
SCHEMBL7950620 0.93 CYP2C9 (0.43) CYP2C9TACR3OPRL1MEN1ALDH1A1
SCHEMBL11917788 0.90 CYP2C9 (0.46) CYP2C9TACR3OPRL1MEN1ALDH1A1
SCHEMBL7950413 0.90 CYP2C9 (0.46) CYP2C9TACR3OPRL1MEN1ALDH1A1
SCHEMBL11917795 0.90 CYP2C9 (0.46) CYP2C9TACR3OPRL1MEN1ALDH1A1
SCHEMBL11917792 0.90 CYP2C9 (0.46) CYP2C9TACR3OPRL1MEN1ALDH1A1
SCHEMBL11917789 0.87 CYP2C9 (0.44) CYP2C9TACR3OPRL1MEN1ALDH1A1
SCHEMBL7942750 0.87 CYP2C9 (0.44) CYP2C9TACR3OPRL1MEN1ALDH1A1
SCHEMBL7949109 0.86 CYP2C9 (0.49) CYP2C9TACR3PDE2A
SCHEMBL11917799 0.86 CYP2C9 (0.49) CYP2C9TACR3PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed
WO-2010028655-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 CYP2C9 3674/4885TACR3 34/4885OPRL1 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.